US Broker Ratings

Abivax SA (ABVX) Stock Analysis: A 72.87% Potential Upside in the Biotech Sector

Abivax SA (ABVX) is making waves in the biotechnology industry with its promising clinical-stage developments. Headquartered in Paris, France, Abivax is firmly positioned within the healthcare..

Simulations Plus, Inc. (SLP) Stock Analysis: Navigating the Healthcare Software Landscape with a Steady Growth Trajectory

Simulations Plus, Inc. (NASDAQ: SLP) stands as a notable player within the healthcare sector, specifically in the health information services industry. Headquartered in Research Triangle Park,..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: A Biotech Pioneer with Over 111% Potential Upside

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company based in Carlsbad, California, is making significant strides in the healthcare sector with its precision medicine platform,..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: A 52.72% Potential Upside Awaits Investors

Relay Therapeutics, Inc. (NASDAQ: RLAY) has emerged as a compelling player in the biotechnology sector, with a market capitalization of $3.89 billion. Headquartered in Cambridge, Massachusetts,..

Bioventus Inc. (BVS) Stock Analysis: Medical Device Innovator with 30% Upside Potential

Bioventus Inc. (NASDAQ: BVS), a prominent player in the healthcare sector, is making waves with its innovative medical devices aimed at relieving pain and improving musculoskeletal..

Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Challenges with Growth Potential in the Medical Device Sector

Avanos Medical, Inc. (NYSE: AVNS), a key player in the healthcare sector specializing in medical devices, presents an interesting case for investors seeking exposure to innovative..

Organogenesis Holdings Inc. (ORGO) Stock Report: Analyzing the 40.85% Potential Upside

For investors with a keen eye on the biotechnology sector, Organogenesis Holdings Inc. (ORGO) presents an intriguing case. Despite its challenges, the company boasts a potential..

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a 225% Potential Upside in the Biotech Arena

In the ever-evolving landscape of biotechnology, Humacyte, Inc. (NASDAQ: HUMA) stands out with a compelling potential upside of 225%, according to analyst ratings. With its innovative..

Amylyx Pharmaceuticals (AMLX): Investor Outlook with a 40% Potential Upside

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, is making waves in the healthcare sector with its promising pipeline of treatment..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Evaluating a 62% Upside Potential in the Healthcare Sector

Emergent BioSolutions Inc. (NYSE: EBS) has recently caught the attention of investors with a striking potential upside of 62.48%, as calculated from analyst target price evaluations...

Talkspace, Inc. (TALK) Stock Analysis: Exploring a 21.43% Potential Upside in the Healthcare Sector

Talkspace, Inc. (NASDAQ: TALK) is a name that has been making waves in the healthcare sector, particularly within the realm of virtual behavioral health services. As..

Prothena Corporation plc (PRTA) Stock Analysis: A Potential 157% Upside in the Biotechnology Arena

Prothena Corporation plc (NASDAQ: PRTA) is a key player in the biotechnology sector, focusing on novel therapies for diseases caused by protein dysregulation. With a market..

Pharvaris N.V. (PHVS) Stock Analysis: Unveiling a Potential 75% Upside in Biotech

Pharvaris N.V. (PHVS), a Swiss-based biopharmaceutical company, has recently captured the attention of investors with its strategic focus on therapies for rare diseases, particularly angioedema. With..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Assessing a 326% Upside Potential

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company dedicated to developing therapeutics for kidney disease patients, presents a compelling prospect for investors seeking high-risk, high-reward opportunities..

Zymeworks Inc. (ZYME) Stock Analysis: Exploring a 53.79% Potential Upside for Biotech Enthusiasts

Zymeworks Inc. (NASDAQ: ZYME), a US-based biotechnology company, is making waves in the healthcare sector with its innovative approach to developing biotherapeutics for cancer, inflammation, and..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Promising 59.92% Upside in the Biotech Arena

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is capturing investor attention with a potential upside of nearly 60%, according to the latest analyst ratings. As a clinical-stage biopharmaceutical..

Ardelyx, Inc. (ARDX) Stock Analysis: Unveiling a 273.91% Potential Upside

Ardelyx, Inc. (NASDAQ: ARDX), a biotechnology company headquartered in Waltham, Massachusetts, has captured investor attention with its promising potential upside of 273.91%. Operating within the healthcare..

Cel-Sci Corporation (CVM) Stock Analysis: Exploring a 626% Upside Potential in Biotech

Cel-Sci Corporation (NASDAQ: CVM) presents a captivating opportunity for investors intrigued by the potential of biotechnology firms within the healthcare sector. With a market capitalization standing..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 92% Upside Potential in Biotech

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a biotechnology company focused on innovating treatments for chronic coughs, presents an intriguing investment opportunity for those interested in the healthcare..

Embecta Corp. (EMBC) Stock Analysis: Exploring the Healthcare Innovator’s Potential Despite a 28.83% Downside

As investors continue to navigate the complexities of the healthcare sector, Embecta Corp. (EMBC) presents a compelling case for analysis. With its roots firmly planted in..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds